TICKERNERD
Menu
BLFSBLFSHealthcare · Medical Instruments & Supplies

BLFS Stock Forecast: BioLife Solutions, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$35
+1.36% on the day

The 9 Wall Street analysts covering BioLife Solutions, Inc. hold a median 12-month price target of $31 — -12.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 14 Sept 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$1.7B
Ticker Nerd rank
91 / 100
Median analyst target
$31
Analysts covering
9
Revenue$28.5M+12.0% y/y
Operating income$1.7M
Net income$45.1M
Free cash flow$5.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.5%
1M
+1.0%
YTD
+46.5%
1Y
+38.9%
From 52W high
−4.8%
From 52W low
+95.2%
$18
$37
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BLFS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BioLife Solutions, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
91 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
92
Revisions
86
Momentum
82
Growth
80
Issuance
71
Volatility
71
Value
70
Size
38
Accruals
19

Quality (92): The business earns solid, repeatable profits on what it owns.

Accruals (19): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BLFS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BLFS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26BLFSHigh $33Median $31Low $31

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
1 Buy8 Hold0 Sell
Low $31Median $31High $33

The green dot is the last close — the median target sits −12.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
10 Aug 2026BenchmarkDowngradeHold—
27 July 2026Stephens & Co.DowngradeEqual-Weight—
27 July 2026Stephens & Co.DowngradeEqual-Weight$32 → $31
23 July 2026JefferiesDowngradeHold$30 → $31
23 July 2026JefferiesDowngradeHold—
23 July 2026TD CowenDowngradeHold—
23 July 2026TD CowenDowngradeHold$33 → $31
22 July 2026HC Wainwright & Co.DowngradeNeutral—
22 July 2026HC Wainwright & Co.DowngradeNeutral$32 → $31
22 July 2026Lake StreetDowngradeHold—
22 July 2026Lake StreetDowngradeHold$33 → $31
29 Dec 2025HC Wainwright & Co.ReiteratesBuy$32
29 Dec 2025HC Wainwright & Co.ReiteratesBuy—
24 Nov 2025HC Wainwright & Co.ReiteratesBuy—
8 Aug 2025HC Wainwright & Co.MaintainsBuy—
13 May 2025HC Wainwright & Co.ReiteratesBuy—
6 Mar 2025HC Wainwright & Co.MaintainsBuy—
8 Jan 2025Northland Capital MarketsMaintainsOutperform—
19 Dec 2024BenchmarkReiteratesBuy—
13 Dec 2024KeybancMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BLFS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BLFS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, BioLife Solutions, Inc. returned +38.9% against +17.0% for the S&P 500, dividends included.

BLFS vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Oct 25Jan 26Apr 26Jul 26BLFSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BLFS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+50.0%
Analysts raising
0
Analysts cutting
1
Fundamentals

BioLife Solutions, Inc. (BLFS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
35.0×

Cheaper than 22% of US stocks

Price / sales
16.0×

Cheaper than 10% of US stocks

Price / book
4.1×

Cheaper than 25% of US stocks

EV / EBITDA
238.1×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
21.5%

Higher than 71% of US stocks

Earnings growth (YoY)
12.0%

Higher than 50% of US stocks

Gross margin
64.2%

Higher than 77% of US stocks

Operating margin
6.0%

Higher than 57% of US stocks

Net margin
54.3%

Higher than 96% of US stocks

Returns & dividend
Return on equity
12.8%

Higher than 70% of US stocks

Return on assets
0.3%

Higher than 44% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

BioLife Solutions, Inc. (BLFS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BioLife Solutions, Inc. has a market value of $1.7B and an enterprise value of $1.6B.

  • Revenue in the twelve months to 30 June 2026: $102.8M. The latest quarter grew 21.5% year on year.

  • Net income over the same four quarters: $58.0M, a 56.4% net margin.

  • Diluted earnings per share, trailing twelve months: $1.16.

  • Free cash flow in the twelve months to 30 June 2026: −$2.2M.

  • Shares outstanding: 48.9M.

  • Trailing P/E: 35.0×; forward P/E: 105.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • BioLife Solutions, Inc. employs 155 people — $663K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

BLFS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
BLFSBioLife Solutions, Inc.$1.7B
91
LMATLeMaitre Vascular, Inc.$1.8B
69
AZTAAzenta, Inc.$1.5B
81
XRAYDentsply Sirona, Inc.$2.1B
92
KMTSKestra Medical Technologies Ltd.$1.4B
22
STAASTAAR Surgical Co.$1.2B
73
ATRCAtriCure, Inc.$2.8B
94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BioLife Solutions, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BLFS news & analysis

BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

Business Wire · 10 Sept 2026neutral

Law firm Kahn Swick & Foti, led by former Louisiana Attorney General Charles C. Foti, Jr., is investigating the adequacy of the price and process in the proposed acquisition of BioLife Solutions by Repligen Corporation. Under the proposed terms, BioLife shareholders would receive $11.25 in cash and 0.1442 shares of Repligen common stock per BioLife share.

Why it matters — A BLFS watcher would care because the investigation could raise questions about the fairness of the proposed acquisition price and process for shareholders.

BLFS Stock Alert: Halper Sadeh LLC is Investigating Whether BioLife Solutions, Inc. is Obtaining a Fair Price for its Shareholders

Business Wire · 29 Aug 2026negative

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of BioLife Solutions, Inc. to Repligen Corporation for $11.25 per share in cash plus 0.1442 shares of Repligen common stock. The investigation concerns whether BioLife is obtaining a fair price for its shareholders, and the firm is encouraging shareholders to learn about their rights and options.

Why it matters — A BLFS watcher would care because the investigation raises questions about whether the proposed acquisition price adequately compensates shareholders.

BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Surpass Estimates

Zacks Investment Research · 6 Aug 2026positive

BioLife Solutions, Inc. reported second-quarter earnings of $0.04 per share, surpassing the Zacks Consensus Estimate of a loss of $0.01 per share. This compares with break-even earnings per share in the same quarter a year earlier.

Why it matters — The results represent a clear improvement over both analyst expectations and the prior-year period, which a BLFS watcher would find notable.

BioLife Solutions Reports Second Quarter 2026 Financial Results

PRNewsWire · 6 Aug 2026positive

BioLife Solutions reported second quarter 2026 financial results, with total revenue of $28.5 million, up 21% over Q2 2025, GAAP gross margin of 64%, and non-GAAP adjusted EBITDA of $7.4 million. The company also noted that Repligen is expected to acquire BioLife, with the transaction expected to close in the fourth quarter of 2026.

Why it matters — A BLFS watcher would care because the results show revenue growth and profitability, while the announced Repligen acquisition represents a major corporate development expected to close in late 2026.

The London Company Large Cap Vs. Russell 1000 Q2 2026 Portfolio Review

Seeking Alpha · 5 Aug 2026neutral

The London Company's Large Cap portfolio returned 10.9% in Q2 2026 versus a 15.1% increase in the Russell 1000 Index. The firm highlighted ENTG as a top contributor on improving fab utilization and AI-driven semiconductor demand, while RSG declined despite a solid quarter due to softer Environmental Solutions results and weak construction-related volumes.

Why it matters — BioLife Solutions is not mentioned in this portfolio review, so the report offers no direct insight into BLFS; however, BLFS watchers may find it useful for general market context on fund positioning.

FAQ

Frequently asked questions about BLFS stock

What is the BLFS stock price forecast for 2026-2027?

The 9 Wall Street analysts covering BioLife Solutions, Inc. have a median 12-month price target of $31, with estimates ranging from $31 to $33. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BLFS stock a buy right now?

Of the 9 analysts covering BioLife Solutions, Inc., 1 rate it a Buy, 8 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioLife Solutions, Inc. 91 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BLFS?

As at 14 Sept 2026, BioLife Solutions, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (92 of 100).

Will BLFS stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies -12.5% from the last close, and Ticker Nerd's factor model ranks BioLife Solutions, Inc. 91 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BLFS stock forecast for 2030?

No analyst covering BioLife Solutions, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BLFS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $31 to $33 over the next 12 months.

How has BLFS stock performed over the past year?

BioLife Solutions, Inc. returned +38.9% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioLife Solutions, Inc. do?

BioLife Solutions Inc. is a life sciences tools company that develops, manufactures, and markets bioproduction products and services for the cell and gene therapy industry.

What is the latest news on BLFS?

The most recent item we track (Business Wire, 10 Sept 2026): "BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS". Law firm Kahn Swick & Foti, led by former Louisiana Attorney General Charles C. Foti, Jr., is investigating the adequacy of the price and process in the proposed acquisition of BioLife Solutions by Repligen Corporation. Under the proposed terms, BioLife shareholders would receive $11.25 in cash and 0.1442 shares of Repligen common stock per BioLife share.

Company

About BioLife Solutions, Inc.

BioLife Solutions Inc. is a life sciences tools company that develops, manufactures, and markets bioproduction products and services for the cell and gene therapy industry. BioLife Solutions Inc. focuses on helping protect the viability and integrity of biologic materials throughout collection, processing, storage, transport, and thawing. Its product portfolio includes biopreservation media, cell-processing consumables, cryogenic storage containers, automated thawing systems, and cold-chain management solutions. These offerings are used by cell therapy developers, biopharmaceutical companies, contract development and manufacturing organizations, biobanks, and research institutions that work with sensitive living cells and other advanced biologic materials. The company serves customers across the United States and international markets, supporting research, clinical development, and commercial manufacturing workflows in regenerative medicine and related fields.

CEO Mr. Roderick de Greef · 155 employees · United States · https://www.biolifesolutions.com